Here is the response from Galen
"I believe the confusion may arise from not factoring in the conversion of the differing sugars contained in glucose syrup to anhydrous glucose equivalents on digestion.
Rapilose is specifically designed to deliver the equivalent of 75g of anhydrous glucose as per WHO 2hr OGTT guidelines.
Each 300ml solution pouch contains 86.4g of glucose syrup, which is a combination of simple and complex sugars, including mono-, di-, and tri-saccharides. However, on drying these produce a dry glucose amount of 71.5g per 300ml of liquid, which corresponds to the carbohydrate content that we quote in the pack nutritional information.
However, a further hydrolysis factor must be taken into account for each sugar type to show the conversion of these carbohydrates to anhydrous glucose (dextrose) equivalents on digestion. Applying these hydrolysis factors derives the requisite quantity of 75g of anhydrous glucose.
Additionally, given that all glucose syrups contain slightly differing ratios of sugars, each batch of Rapilose solution is further titrated using glucose monohydrate to cater for any small variations in the sugar content allowing us to deliver a precise total anhydrous glucose content of 75g ±1% per 300ml.
I trust this answers your question, however, should you require any additional information please do not hesitate to get in touch. Thank you for your interest in Rapilose OGTT.
Kind regards"
My comments:
di-saccharides are things like fructose, maltose, dextrose, lactose and galactose
tri-saccharides are triple compounds of glucose and fructose with galactose.called the oligosaccharides.
Question. does the use of syrup produce an insulin response comparable to that of dextrose alone. Does for instance fructose or galactose trigger a reaction at all when taken orally. It may do if used in an intravenous application like IVGTT which does not get require enzyme reaction from amylase, lactase or protase. I wonder what tests were done to verify this response.
Actually I found it, seems legit. Apparently this is the same evidence that Lucozade references in their attempt to offer their product for OGTT use.
https://pubmed.ncbi.nlm.nih.gov/13632059/